AstraZeneca has licensed six coronavirus-neutralising antibody candidates from Vanderbilt University (VU) in the US, with plans to advance two into clinical development to prevent and treat Covid-19.

The company has assessed the ability of more than 1,500 monoclonal antibodies (mAbs) to attach to the SARS-CoV-2 virus and block it from infecting healthy cells in a laboratory setting.

Based on these pre-clinical findings, the company has entered an exclusive licence agreement for six antibody candidate currently in VU’s portfolio that targets the novel coronavirus.

Two of these antibodies will be progressed into clinical evaluation as a combination therapy in the coming two months.

MAbs work similarly to natural antibodies and an antibody-based treatment is expected to neutralise the SARS-CoV-2 virus, allowing its use as a preventative option, as well as treatment, noted AstraZeneca.

AstraZeneca BioPharmaceuticals R&D executive vice-president Mene Pangalos said: “By combining two monoclonal antibodies that bind to distinct parts of the SARS-CoV-2 spike protein into what potentially could be a single preventative therapy, we hope to improve its effectiveness in neutralising the virus.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“These collaborations help ensure potential medicines that can prevent or treat Covid-19 are accelerated as quickly and safely as possible.”

The company has also signed an interagency agreement with the US Defense Advanced Research Projects Agency and the Biomedical Advanced Research and Development Authority to support the development of a mAb treatment against Covid-19.

AstraZeneca added that the support will cover Phase I clinical trial and the production of the investigational product for testing in Phase I.

Last month, the company received more than $1bn from the Biomedical Advanced Research and Development Authority to develop, manufacture and deliver a Covid-19 vaccine developed by the University of Oxford.